Challenges in treating cancers of unknown primary (CUP)

Thomas Helleday, MD, PhD, Karolinska Institute, Stockholm, Sweden & University of Sheffield, Sheffield, UK, highlights the issues with treating cancers of unknown primary (CUP), which result in a poor prognosis for patients. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.